Fast Titration Of Quetiapine Versus Currently Approved Titration

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Psychotic Disorders

Treatments: Drug: Quetiapine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00254813

D1449L00003

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and tolerability of a more rapid dose titration in acute schizophrenic patients compared to the conventional titration.

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent, male or female between 18 and 60 years old, having acute exacerbation of their schizophrenia or schizoaffective disorder requiring admission to hospital. Should stay in hospital for at least 7 days.

Exclusion criteria

• Patients treated with Risperdal consta or Clozapine last 28 days, pregnancy or breast-feeding, patients known to be intolerant or unresponsive to quetiapine, known arrhythmia, other serious medical conditions.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)